2026 IAPM/IOF/ECTS/ESCEO/IMS/EMAS Joint Position Statement: Pregnancy- and Lactation-Related Osteoporosis

Full title: Joint Position Statement on Pregnancy- and Lactation-Related Osteoporosis (PLO), co-sponsored by IAPM (International Academy on Perinatal Medicine), IOF (International Osteoporosis Foundation), ECTS (European Calcified Tissue Society), ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases), IMS (International Menopause Society), EMAS (European Menopause and Andropause Society), 2026 Core positioning: First multidisciplinary international consensus specifically for PLO, distinguishing PLO from other metabolic bone diseases; emphasizes that bone loss during late pregnancy and lactation is largely physiological and reversible after weaning, but vertebral fractures occurring in this period require targeted evaluation and management. Strongly emphasizes multidisciplinary obstetrics + endocrinology/metabolic bone + pediatrics; addresses medication safety during pregnancy/lactation and future pregnancy risk counseling.

一、Definitions and Classification

Pregnancy- and Lactation-Related Osteoporosis (PLO) Bone fragility fracture occurring during late pregnancy or within 6 months postpartum, characterized by rapid bone loss and multiple vertebral compression fractures, in the absence of other secondary causes.

• Typical presentation: severe back pain in late pregnancy or early postpartum, multiple vertebral compression fractures;
• Epidemiology: rare, incidence estimated ~0.4/100,000 pregnancies; more common in first pregnancy, late trimester;
• Underlying physiology: pregnancy and lactation require 200–300 mg calcium transfer per day to fetus/infant; maternal bone undergoes reversible demineralization; most women recover BMD within 6–12 months after weaning. PLO represents an exaggerated pathological response in susceptible individuals.

Classification

1. Pregnancy-associated osteoporosis (PAO): onset during pregnancy;
2. Lactation-associated osteoporosis (LAO): onset during lactation;

Both share similar clinical features and management principles.

二、Pathophysiology

1. Physiologic: increased maternal intestinal calcium absorption; lactation requires calcium mobilization from maternal skeleton under PTHrP + low estrogen;
2. Pathologic predisposing factors:
   • Genetic: rare monogenic osteoporosis (LRP5, WNT1), pre-pregnancy low peak bone mass;
   • Secondary causes: vitamin D deficiency, celiac disease, hyperparathyroidism, glucocorticoid use, anorexia;
   • Mechanical: rapid weight gain, posture changes.

PLO is not simply "breastfeeding causes osteoporosis"; breastfeeding alone does not cause fractures in normal women.

三、Clinical Presentation and Diagnosis

Red flags

• New severe midline back pain in late pregnancy or first months postpartum;
• Thoracic/lumbar vertebral tenderness; height loss;
• Multiple vertebral compression fractures on imaging.

Workup

1. Imaging: vertebral fracture assessment (VFA) on DXA; thoracic/lumbar spine X-ray; MRI if pain severe or neurologic symptoms;
2. DXA BMD: technically difficult during late pregnancy; postpartum DXA at 3 months; Z-score ≤−2.0 in reproductive-age women indicates low bone mass for age;
3. Biochemistry: calcium, phosphate, ALP, 25(OH)D, PTH, renal function; thyroid function; celiac serology;
4. Secondary causes: rule out malignancy, infection, multiple myeloma, pre-existing primary osteoporosis;
5. Genetic testing if recurrent fractures or very low BMD in young patients.

Note: DXA during pregnancy is generally avoided due to fetal radiation exposure; ultrasound and MRI preferred for acute evaluation.

四、Management Principles

1. Non-pharmacologic (foundation)

• Calcium: 1000–1200 mg/day dietary + supplement;
• Vitamin D: 800–1000 IU/day; maintain 25(OH)D ≥ 30 ng/mL;
• Weight-bearing exercise as tolerated; avoid high-impact during acute fracture pain;
• Fall prevention; back bracing for vertebral fractures;
• Pain management: avoid NSAIDs in late pregnancy and during lactation when possible; acetaminophen first-line; opioids only short-term under specialist supervision.

2. Lactation recommendations

• Exclusive breastfeeding is not contraindicated for PLO; weaning is not mandatory;
• However, if severe multiple vertebral fractures, rapidly progressive bone loss, or poor fracture healing, early weaning may be considered on an individual basis to accelerate maternal bone recovery;
• Lactation should not be prolonged beyond 6 months in severe PLO cases without specialist supervision;
• Formula feeding is an option after full risk-benefit discussion.

3. Anti-osteoporosis medications

表格

Key principle: Anti-resorptive therapy should be reserved for severe, multi-fracture PLO, after MDT discussion. Calcium + vitamin D + lactation management are sufficient for most mild cases. Teriparatide may be considered postpartum after weaning for vertebral fracture healing.

4. Pain and rehabilitation

• Acute fracture: physical therapy, supervised mobilization;
• Avoid prolonged bed rest (worsens bone loss);
• Pelvic/back support garments.

五、Future Pregnancy Counseling

1. PLO in first pregnancy does not necessarily preclude future pregnancy, but recurrence risk is elevated;
2. Pre-conception evaluation: DXA, 25(OH)D, secondary workup;
3. Pre-conception optimization: ensure vitamin D replete, adequate calcium intake, maintain healthy weight;
4. If bisphosphonate was used after first PLO, discuss washout period (long half-life) before next pregnancy;
5. Close obstetric + metabolic bone monitoring in future pregnancies;
6. Breastfeeding duration in future pregnancies should be planned in advance.

六，Long-term Follow-up

1. DXA at 3, 6, 12 months postpartum to assess BMD recovery;
2. Most women recover BMD within 1–2 years after weaning;
3. Monitor for delayed recovery, persistent vertebral deformity;
4. Long-term fracture risk assessment; encourage lifelong bone-healthy lifestyle;
5. Hormonal contraception consideration: combined hormonal contraception may be considered after weaning to support bone health.

七，Special Populations

1. Adolescent pregnancy: peak bone mass not yet achieved; higher risk; more aggressive monitoring;
2. Recurrent PLO: evaluate for monogenic osteoporosis, celiac disease, hypophosphatasia;
3. PLO with concomitant gynecologic cancer survivors: cross-reference FIGO 2026 menopause position statement; MHT decisions need combined oncology + metabolic bone input.

八，Evidence Gaps

1. No RCTs on anti-resorptive use in PLO; evidence from case series and observational cohorts;
2. Optimal duration of lactation in PLO remains debated;
3. Long-term (10–20 year) fracture risk after PLO is not well quantified;
4. Genetic basis of idiopathic PLO largely unknown;
5. Denosumab rebound effect in postpartum setting is a recognized concern requiring careful planning.

九，Cross-Reference with Prior Guideline Series

1. This 2026 joint position statement: pregnancy/lactation-related osteoporosis, bone metabolism in reproductive years;
2. FIGO 2026 gynecologic cancer survivors menopause position: addresses MHT in cancer survivors; bone health is one domain; PLO is a separate acute bone fragility condition;
3. 2026 International Multidisciplinary Consensus on Incretins in Women's Reproductive Health: GLP-1 drugs in reproductive-age women; weight loss may affect bone health, requiring calcium/vitamin D supplementation (cross-reference);
4. 2026 Italian Postoperative Hypoparathyroidism guideline: calcium/PTH management; hypocalcemia in postpartum may overlap;
5. SMS 2026 menopause obesity statement: bone protection during weight loss; PLO shares similar principles of protein + resistance training + vitamin D.

免责声明

This summary is for academic learning only, not direct clinical practice. Management of pregnancy/lactation-related osteoporosis requires obstetric + endocrinology/metabolic bone MDT. Anti-osteoporosis medications during pregnancy and lactation require individualized risk-benefit assessment.